市場調查報告書
商品編碼
1404039
生物標記發現外包服務市場-按類型(預測、預後、安全性、替代終點)、服務(基因組學、蛋白質組學、生物資訊學)、治療領域(腫瘤學、心臟病學、心血管)、最終用途全球預測2024-2032Biomarker Discovery Outsourcing Services Market-By Type (Predictive, Prognostic, Safety, Surrogate Endpoints), Service (Genomics, Proteomics, Bioinformatics), Therapeutic Area (Oncology, Cardiology, Cardiovascular), End-use Global Forecast 2024-2032 |
在產業領導者增加投資和擴張的推動下,全球生物標記發現外包服務市場在 2024 年至 2032 年間的CAGR將達到 12.7%。隨著知名公司擴大研發計劃,對外包生物標記發現服務的需求也隨之增加。
例如,2022 年 10 月,賽默飛世爾的臨床研究部門 PPD 撥款 5,900 萬美元,用於增強肯塔基州疫苗、細胞和基因治療的樣本管理和測試能力。此舉符合 Thermo Fisher 的全球策略,旨在為臨床研究提供全面的實驗室和生物標記服務。 PPD 位於肯塔基州高地的現有 71,600 平方英尺設施目前提供中央實驗室服務和生物標記業務,並為生物製藥客戶提供支援。
該市場迎合不同領域,包括製藥和診斷,提供識別疾病和治療的關鍵生物標記的專業知識。對個人化醫療和精準診斷的日益關注推動了這一需求,促使公司外包這些服務以獲取創新見解,從而推動市場的成長和演變。
生物標記發現外包服務市場的總體佔有率根據類型、最終用途和地區進行分類。
預測性生物標記領域將在 2024 年至 2032 年間經歷重大發展。這些標記物在預測疾病進展、治療反應和患者結果方面發揮關鍵作用。隨著精準醫學的發展勢頭,製藥和生物技術產業加強尋找預測性生物標記。專門從事生物標記發現的外包服務變得至關重要,有助於識別和驗證這些預測指標。市場的成長與對個人化治療的追求相一致,強調了預測生物標記在徹底改變患者護理和治療效果方面的重要性。
從 2024 年到 2032 年,製藥公司領域的生物標記發現外包服務市場規模將出現顯著的複合CAGR。隨著藥物開發轉向精準醫療,對可靠生物標記的需求不斷加劇。對於旨在有效識別、驗證和利用生物標記的製藥公司來說,外包這些服務變得至關重要。該市場滿足多樣化的需求,提供生物標記發現的專業知識,並協助藥物開發、臨床試驗和個人化醫療。對生物標記的高度依賴推動了市場的成長,展示了其在推進藥物研究和治療創新方面的關鍵作用。
歐洲生物標記發現外包服務產業將在 2024 年至 2032 年呈現出值得稱讚的CAGR。該地區的製藥和生物技術行業越來越依賴外包專業知識來識別和驗證對客製化療法至關重要的生物標記。歐洲產業專注於推動個人化醫療和加速藥物開發,尋求生物標記發現的專業外包服務。
這種需求反映了歐洲對創新醫療保健解決方案的承諾,並強調了市場在塑造歐洲大陸醫學研究和治療的未來方面的關鍵作用。例如,2023 年 10 月,Almac 集團宣布斥資 8,000 萬英鎊,在其位於北愛爾蘭克雷加文的全球基地建造大型製造、生產和診斷實驗室設施。 Almac Diagnostic Services 為全球生物製藥合作夥伴提供多樣化的生物標記發現、開發和商業化解決方案。
Global Biomarker Discovery Outsourcing Services Market will witness 12.7% CAGR between 2024 and 2032, buoyed by increased investments and expansions by industry leaders. As prominent companies expand their research and development initiatives, the need for outsourced biomarker discovery services amplifies.
For instance, in October 2022, Thermo Fisher's clinical research arm, PPD, allocated $59 million toward enhancing sample management and testing capabilities for vaccines, cell, and gene therapy in Kentucky. This move aligned with Thermo Fisher's global strategy, aiming to furnish comprehensive lab and biomarker services for clinical research. PPD's existing 71,600 square-foot facility in Highland Heights, Kentucky currently houses central lab services and biomarker operations and supports biopharmaceutical clients.
This market caters to diverse sectors, including pharmaceuticals and diagnostics, offering expertise in identifying crucial biomarkers for diseases and treatments. The rising focus on personalized medicine and precision diagnostics fuels this demand, prompting companies to outsource these services for innovative insights, driving the market's growth and evolution.
The overall Biomarker Discovery Outsourcing Services Market share is classified based on the type, end-use, and region.
Predictive biomarkers segment will undergo significant development from 2024 to 2032. These markers play a pivotal role in forecasting disease progression, treatment response, and patient outcomes. As precision medicine gains momentum, pharmaceutical and biotech sectors intensify efforts to identify predictive biomarkers. Outsourcing services specialized in biomarker discovery become crucial, aiding in the identification and validation of these predictive indicators. The market's growth aligns with the quest for personalized therapeutics, emphasizing the significance of predictive biomarkers in revolutionizing patient care and treatment efficacy.
Biomarker discovery outsourcing services market size from the pharmaceutical companies segment will register a noteworthy CAGR from 2024 to 2032. As drug development pivots towards precision medicine, the quest for reliable biomarkers intensifies. Outsourcing these services becomes pivotal for pharmaceutical firms aiming to identify, validate, and utilize biomarkers efficiently. This market caters to diverse needs, offering expertise in biomarker discovery and aiding in drug development, clinical trials, and personalized medicine. The heightened reliance on biomarkers fuels the market's growth, showcasing its pivotal role in advancing pharmaceutical research and therapeutic innovations.
Europe biomarker discovery outsourcing services industry will showcase a commendable CAGR from 2024 to 2032. The region's pharmaceutical and biotech sectors increasingly rely on outsourced expertise to identify and validate biomarkers crucial for tailored therapies. With a focus on advancing personalized medicine and accelerating drug development, European industries seek specialized outsourcing services in biomarker discovery.
This demand reflects Europe's commitment to innovative healthcare solutions and underscores the market's pivotal role in shaping the future of medical research and therapeutics on the continent. For instance, in October 2023, Almac Group announced an £80 million initiative to construct expansive manufacturing, production, and diagnostic laboratory facilities at its global base in Craigavon, Northern Ireland. Almac Diagnostic Services delivers diverse biomarker discovery, development, and commercialization solutions to global biopharmaceutical partners.